Dr Sean Leng and the Johns Hopkins-SunInflam tea
Author: Michael
LW-1017, an oral drug that switches the brain’
One-year results for the open-chest version look
Amorepacific deal puts therapeutic target discov
AbbVie announced that the FDA has approved Juvmo
Arvinas announced that the first participant has
4DMT has enrolled first patients in its 4SIGHT gl
A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down. With thanks to MuseCell Innovations, sponsor of the Longevity Biotech Report. The $230 billion pipeline needs nothing from anyone. It exists inside disease categories regulators already recognize, using approval routes already walked a thousand times over. The $173 billion sitting on top of it is a rather different proposition. It requires a category that does not yet exist – a recognized gerotherapeutic endpoint – to come into being first, and everything about its size depends on when, or whether,…
The 4th Roundtable of Longevity Clinics meets at
Resolution Therapeutics has treated its last EME